Pharmaceutical leader turns to compound producer to assist in development of new screening library
Maybridge, a producer and supplier of organic compounds for drug discovery and development in the pharmaceutical, biotechnology and agrochemical industries, and Roche, one of the world's leading research-oriented healthcare groups, have announced ythat the two companies will collaborate on the creation of a proprietary screening library, based on Maybridge's novel collection of Reactive Intermediates.
Once completed, the new library will be owned and maintained exclusively by Roche.
The detailed collaboration will entail Maybridge and Roche scientists working closely to develop the new library, as both companies bring key elements to the table.
Maybridge, known for its skills in heterocyclic organic chemistry, offers one of the best commercially available monomer libraries of diverse reactive intermediates for hit-to-lead optimization.
Roche will apply its proprietary approach to their library design as well as over 100 years of industry experience.
"Maybridge is pleased to have this opportunity to work with a well-respected and leading pharmaceutical company, like Roche," said Nick Kerton, chief executive officer.
"Roche's desire to add proprietary and unique library compounds by leveraging
